Biocon acquires shares in Biocon Biologics for $1.2 billion
pre-market1 source ↓written by the desknot a recommendation
Biocon Limited has successfully acquired minority shareholdings in Biocon Biologics Limited for USD 1.2 billion. This strategic move involves purchasing shares from Viatris, Serum Institute Lifesciences, Tata Capital Growth Fund II, and True North. This acquisition may enhance Biocon's market position and operational capabilities in the biopharmaceutical sector.
Key Points:
• Transaction value: USD 1.2 billion
• Involves multiple stakeholders
• Potential for increased market share
Traders may watch for market reactions following this significant acquisition.
Not investment advice. For informational purposes only.